- Development of HFA-152a as an environmentally sustainable propellant for pressurized metered dose inhalers
- Inhaled administration of drugs to animals in pharmaceutical research
- Particle engineering approaches for dry powder inhalers
- Cascade impactor stage groupings: Poor decisions from degraded data
- Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
- Nasal and trans-nasal lung deposition of aerosols
- Gaining new insights into pressurized metered dose inhaler (pMDI) design using synchrotron radiation
- The liability of fine particle dose (FPD)
- A clinically relevant approach to assess in vitro bioequivalence for regulatory approval of DPIs: A case study
- Accelerating inhalation product development: Choosing between outsourcing and developing internal capabilities
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part II: The concept of “sufficient” as applied to impactor quality specifications
- Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug products
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2019)
- An update on solid-state physicochemical characterization and microscopy of particles in dry powder inhalers
- Technology selection in capsule-based inhalation product development
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part I: A grassroots look
- Testing and comparison of puncturing forces for gelatin and HPMC inhalation capsules
- Spray pattern as a screening tool during early development of nasal sprays
- Applications of automated scanning electron microscopy—energy dispersive spectroscopy (SEM-EDS) for inhalable drug products
- The regulatory landscape for OINDPs—the biggest shake-up in a generation?
- Point of View: Recommendations to a young scientist to pursue inhalation research
- Defining the dosage strength for labeling of DPIs: Use, limitations and relevance of in vitro data
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 2—Informative chapters <1601>, <1602>, <1603> and <1604>
- Respirable, engineered, spray-dried dry powders for 505(b)(2) drug product development
- Spray-granulated mannitol as a viable alternative to lactose in DPI formulations: Preparation of ordered mixtures and storage stability
- Connected inhalers: Stakeholders’ potential benefits and possible concerns
- Combined impactor and x-ray diffraction (XRPD) methodology for characterizing polymorph impurities in inhalation powders
- Progress in particle engineering science: Towards advanced dry powder inhalation systems
- Meeting expectations for FDA nasal spray Q3 structural equivalence
- Nebulizers: Past to present platforms and future possibilities (2018)
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 1—Normative chapters <5>, <601>, <602>, <603> and <604>
- Back Page: Reducing carbon footprints of metered dose inhalers
- Back Page: Mimicking cigarette smoke exposure and patient-specific responses
- Back Page: A free online tutorial about cascade impaction from the IPAC-RS CI working group
- Back Page: Exploring the potential of mannitol as an alternative to lactose in dry powder inhalation
- Back Page: Modeling paradigms for orally inhaled drugs
- Back Page: Exercise induced bronchoconstriction: The role of inhaled therapy in identifying stimulus and mechanism
- Back Page: Rules in pharmacy and music: More in common than you might believe!
- Back Page: Controlled release formulations for inhalation: Soon to appear?
- Back Page: On the design of comparator clinical studies
- The influence of lactose fines in dry powder inhaler formulations
- The importance of human factors in inhaler development: The making of PowdAir®
- The impact of intratracheal aerosol technologies on preclinical pulmonary research
- The Good Cascade Impactor Practice (GCIP) Concept: A systematic approach to risk management of erroneous measurements in the assessment of inhaler emitted aerosol aerodynamic particle size distributions (APSDs)
- The effect of shaking on solution MDIs
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2016)
- Significant restriction of the delivered dose uniformity criteria in the revised USP Chapter for Aerosols
- Significant advances in laboratory testing of orally inhaled products during the ten-year life of Inhalation
- Selecting an MDI can
- Selecting a dose counter
- Redundancy Based Development (RBD) for a dry powder inhaler
- Quality by design: Considerations for inhalation product development
- Product development: Case study of an inhaled biologic
- Principles of nebulizer technology
- PK bioequivalence testing when between-batch variability is high: A multiple-batch proposal
- Pharmacoscintigraphy
- Particle engineering for inhalation formulation and delivery of biotherapeutics
- Particle engineering by practical and scalable, intensive, mechanical, dry coating processes to develop highly efficient dry powder inhaler formulations
- Particle design for respiratory drug delivery: Challenges and processing options
- Parameters to consider in software for respiratory drug and device testing
- Overlooked opportunities for nebulizers in inhalation product development
- Overcoming challenges in development of nasal vaccines through intelligent particle engineering
- Outsourcing inhalation product development
- Opportunities for capsule-based DPIs in emerging markets
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 2—Total Emitted Mass (TEM) and related metrics
- Nebulizers: Past to present platforms and future possibilities (2016)
- Nasal spray regulatory approval
- Nasal drug delivery devices: Past, present and future device innovations for the would-be product developer
- Micromolding as a potential manufacturing route for dry powder formulations
- MDI propellants
- LC-MSD as a platform for inhalation product development
- Interaction of nanomaterials at the air-liquid interface of the lung
- Innovation in analytical tools: More signal and less noise in particle size testing of inhaled products
- Inhaled therapies for tuberculosis: A viable approach for spray-dried drugs delivered by handheld dry powder inhaler
- Inhaled drug product development: A unique form of product life cycle management
- Inhalation to the small airways
- Impact of capsule selection on formulation stability in dry powder inhalers (DPIs)
- Human factors studies in the development of a new nasal delivery device
- High pressure homogenization as an alternative methodology to micronization for obtaining effective inhalation particles
- Good practices for Abbreviated Impaction Measurements (AIM) in dry powder inhalers (DPIs)
- Getting started with CFD
- Gene–environment interactions in asthma: Lessons for the development of new drugs for asthma
- Gaps in statistical approaches to control of delivered dose uniformity throughout product lifecycle
- Functional respiratory imaging (FRI): Enhancing biomarker sensitivity to expedite drug development
- From actuation to deposition: Particle sizing techniques for characterizing nasal drug delivery systems
- Formulation concepts for small-volume nebulizers: Challenges and opportunities
- Formulation and characterization of nasal sprays
- Excipients in DPI Formulations
- Examining the influence of carrier lactose on the performance of dry powder inhaler (DPI) formulations: A case study
- Evolution of nasal aerosol products for pain management
- Evaluating the performance of orally inhaled products in the laboratory: Why clinically appropriate testing is important
- Evaluating the Alberta Throat: An innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development
- Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
- Elastomers in orally inhaled and nasal drug products, Part II: Control strategies
- Elastomers in orally inhaled and nasal drug products, Part I: Elastomer selection and qualification
- Effective inhalation treatment for acute fungal infections
- Effect of conditioning on rat lung function measurements and implications for exposure and dose estimation of inhaled drugs
- DPI development: Understanding the technical challenges
- Development of inhalable dry-powder formulations for low water-soluble products using spray-dried engineered particles
- Developing OINDPs using Quality by Design
- Design of an inhaler-specific robotic system for laboratory use in early development
- Delivery of inhaled bronchodilators by breath-actuated jet nebulizer: The potential for improved adherence with clinical guidelines
- Delivering orally inhaled medications to the older patient with COPD and/or asthma: A challenge in both device design and clinical approach
- CROs and OINDP development
- Critical evaluation of the revised and new USP chapters for aerosols: and [Pharm Forum 2011; 37(4)]
- Contributions of mechanical stress on the “frustrated” thermal response of griseofulvin
- Considerations in spray dry drug development for inhalation delivery: An albuterol case study
- Considerations in selecting a contract manufacturing organization
- The pressurized metered dose inhaler: Past, present and future perspectives
- The role of intelligent sorbents in respiratory drug delivery devices
- The role of the Hydraulic Lung in comparing the performance of dry powder inhalers
- The use of cyclodextrins in formulations for lung delivery
- Comparison between in vitro performance of the Child “Alberta” Idealized Throat and Ph.Eur./USP induction port for the delivery of salbutamol sulfate inhalation aerosol by pressurized metered dose inhaler
- Choosing between capsules and blisters
- Avoiding pitfalls obtaining inhalation patents at the European Patent Office
- Atomic force microscopy (AFM): A quantitative tool for excipient screening of pMDI formulations
- Assessing the role of breathing simulators in OIP testing
- Application of organotypic in vitro human cell culture models for research and development of inhalation pharmaceutical formulations targeting the proximal airways
- Thixotropic sprays: Popular with patients, challenging for developers
- Unveiling dislocations in API crystallinity after mechanical stress due to milling
- Analytical instrumentation for solid state characterization of inhalable formulations
- An approach to particle size stability
- Aerosolized adhesive coating of cascade impactor plates
- Advantages of capsule-based dry powder inhalers
- Addressing the patient-device use interface: Why patient-friendly features are important
- US Payers and OINDPS
- Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts: A partnership for the assurance of Oral Inhaled Product (OIP) quality
- A novel aerodynamic sizing method for pharmaceutical aerosols using image-based analysis of settling velocities
- A forensic approach to particulate contamination in inhalable drug products
- A “smart” move: The development of electronic devices for nasal aerosols
- In vitro particle deposition in the nasal cavity
- Using MDIs to deliver pDNA
- Spray pattern: A rapid and sensitive early development tool for respiratory drug products
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 1—Aerodynamic Particle Size Distribution (APSD)
- Addressing the patient-device use interface: Development and laboratory validation of a facemask with anatomically-responsive face models
- What is the future of HFA pMDIs? A patent-based perspective